Protocol No.: M23-714

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension [Protocol M23-714]
Principal Investigator
Najib, Umer
Phase
III
Age Group
Adult
Applicable Disease Site
Other
Participating Institutions
Health Sciences Center
West Virginia University
Contact
Lauren Chase, RN
Clinical Research Specialist
Phone: +1 304-598-4000

View on ClinicalTrials.gov